Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Wright Reports
|
$460.00
|
|
Provider: GlobalData
|
$250.00
|
|
Provider: GlobalData
|
$125.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Stallergenes SA Appoints Patrick Langlois as Non Executive Chairman of the Board of Directors
Stallergenes SA announced the appointment of Patrick Langlois as non executive Chairman of the Board of Directors, with effect from July 1, 2012. In accordance with his wishes, Albert Saporta, whose term of office as Chairman expires on June 30, 2012, will remain as a member of the Board of Directors to continue to support Stallergenes' development.
Latest Developments for Stallergenes SA
- Stallergenes SA Announces FDA Acceptance For Review Of BLA For Oralair
- Stallergenes SA Issues FY 2012 Operating Profit Guidance Below Analysts' Estimates
- Stallergenes SA Updates FY 2012 Sales Growth Guidance; Confirms FY 2012 Operating Margin Guidance
- Stallergenes SA Confirms FY 2012 Growth Guidance and FY 2012 Operating Margin Outlook
Latest Key Developments in Biotechnology
- Nektar Therapeutics Announces Positive Data From Human Abuse Liability Study For NKTR-181
- Amarantus Bioscience Holdings Inc Reports Positive Results On MANF Neuroprotective Properties Demonstrated In Preclinical Study In China
- BioInvent International AB Implements Rights Issue of Approximately SEK 22 Million; Updates on New CEO Start Date
- Newron Pharmaceuticals SpA's sNN0031 Proves Safety and Efficacy in Phase I/II Study in Parkinson's Disease
- Share this
- Link this
- Digg this
Follow Reuters